| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 43,415 | 43,505 | 23:00 | |
| 43,205 | 43,655 | 22:00 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 650,00 | 4 | |||
| 170,00 | 8 | |||
| 135,00 | 57 | |||
| 60,00 | 15 | |||
| 52,20 | 500 | |||
| 51,76 | 50 | |||
| 43,655 | 189 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/0qf.htm [/URL] | ||||
| 189 | 43,205 | |||
| 100 | 41,000 | |||
| 37 | 36,000 | |||
| 120 | 20,800 | |||
| 1.052 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.498 | 0,549 | 823 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:51 | 44,590 | 4 |
| 17:30:04 | 44,490 | 1 |
| 17:24:41 | 44,625 | 42 |
| 17:24:00 | 44,585 | 38 |
| 17:16:40 | 44,570 | 125 |
| 17:16:40 | 44,570 | 15 |
| 17:16:40 | 44,570 | 48 |
| 17:05:57 | 44,715 | 72 |
| 17:01:55 | 44,830 | 6 |
| 16:57:20 | 44,460 | 203 |
| 16:52:33 | 44,360 | 153 |
| 16:52:33 | 44,340 | 75 |
| 16:43:00 | 44,225 | 57 |
| 16:42:58 | 44,230 | 121 |
| 16:42:57 | 44,310 | 57 |
| 16:40:06 | 44,280 | 159 |
| 16:37:06 | 44,460 | 22 |
| 16:35:16 | 44,045 | 172 |
| 16:29:13 | 43,745 | 123 |
| 16:26:36 | 43,658 | 42 |
| Tagesumsatz Xetra | +0,785 +1,79 % | 5.456 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy? | 41 | Barchart.com | ||
| Di | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | 670 | ACCESS Newswire | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| 03.04. | Top Moderna Shareholders | 22 | Investopedia | ||
| 30.03. | Moderna vor entscheidender Bewährungsprobe | 776 | LYNX Broker | Moderna steht derzeit wieder stärker im Fokus technischer Beobachter. Im Chartbild zeigen sich Hinweise auf eine Stabilisierung Den vollständigen Artikel lesen ... ► Artikel lesen | |
| MODERNA Aktie jetzt für 0€ handeln | |||||
| 27.03. | ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential? | 51 | Zacks |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 14:30 | MetaVia Inc.: MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity | PR Newswire | 16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults
CAMBRIDGE, Mass., April 10, 2026... ► Artikel lesen | |
| 20:29 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.04.2026 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 10.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.04.2026.ISIN NameAU000000ICI5... ► Artikel lesen | |
| 11:57 | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| 11:51 | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| 16:18 | Weekly Buzz: MacroGenics Resumes LINNET; GSK Wins China Nod; FDA Okays Waters Corporation; Neurocrine Biosciences Snaps Up Soleno Therapeutics | AFX News | THOUSAND OAKS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Canada, and China, alongside the lifting of a clinical trial hold by the FDA, collaborations... ► Artikel lesen |